US Markets

Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals


Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday.

COPENHAGEN, Sept 16 (Reuters) - Danish pharmaceutical company Lundbeck LUN.CO will acquire Alder BioPharmaceuticals ALDR.O in a deal valued at almost $2 billion, the company said in a statement on Monday.

The deal, expected to close in the fourth quarter of this year, will be funded through existing cash resources and bank financing, Lundbeck said.

Alder develops preventative treatments of migraine in adults and has submitted a Biologics License Application for its eptinezumab antibody to the FDA in February this year.

Lundbeck will buy outstanding shares of Alders in an upfront payment of $18 per share.

The board of Alders has approved the transaction unanimously.

(Reporting by Nikolaj Skydsgaard Editing by Shri Navaratnam)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at and via Reuters TV.

    Learn More